Chronic Spontaneous Urticaria Refractory to Second-Generation Antihistamines
A 38-year-old man presents with 5 months of daily hives and intermittent lip swelling, no angioedema of the airway, and no identifiable trigger. He has been on cetirizine 10 mg daily for 3 months with partial control; he reports hives on most days and wakes 2-3 nights per week. He has tried adding loratadine 10 mg in the morning without benefit. He asks about 'allergy shots,' a strict elimination diet, and long-term steroids. Labs: CBC normal, TSH normal, CRP normal. He has no history of thyroid disease, no joint pain, no fevers.
1. What is the appropriate next step in pharmacologic management, and what is the reasoning behind dose escalation versus adding a second antihistamine?
Read the worked answer
The diagnosis fits chronic spontaneous urticaria (CSU): recurrent wheals with or without angioedema for >6 weeks without an identifiable external trigger. First-line therapy is a second-generation H1 antihistamine; guidelines support escalating the dose of a single second-generation agent up to 4-fold before declaring failure, because dose-response is not linear and many patients achieve control at 2-4x standard dose. The patient's current regimen (cetirizine 10 mg plus loratadine 10 mg) is essentially two standard-dose agents - combining different antihistamines at standard doses is not equivalent to escalating one agent, and it adds cost and sedation risk without the evidence base that dose escalation has.
So the next step is to increase cetirizine to 10 mg twice daily, then up to 20 mg twice daily if needed, monitoring for sedation (cetirizine is the most sedating of the second-generation agents at higher doses). If he remains uncontrolled at 4x dose, the next step is not steroids - it is referral for omalizumab (anti-IgE), which is the established third-line therapy for antihistamine-refractory CSU.
2. He asks about allergy testing, elimination diets, and prednisone. How do you counsel him on each, and what monitoring is needed if steroids are ever used?
Read the worked answer
Allergy testing: routine testing (skin prick or specific IgE) for foods, inhalants, or 'environmental' triggers is not indicated in CSU without a clear temporal history, because positive results are common in the general population and lead to unnecessary elimination. Testing is indicated only if history suggests a specific trigger (e.g., a reaction reproducibly after a food or drug).
Elimination diets: empiric elimination diets are not recommended in CSU; they risk nutritional deficiency and rarely help. Pseudoallergen-free diets have weak evidence and should not be first-line.
Steroids: short courses of oral corticosteroids may be used for severe flares, but they are not a maintenance therapy - chronic use causes osteoporosis, hyperglycemia, hypertension, weight gain, and adrenal suppression. If used, keep courses short (e.g., 3-5 days), and if repeated courses are needed, that is a signal to escalate to omalizumab rather than to continue steroids. If any prolonged course is contemplated, monitor blood pressure, glucose, and bone health, and taper rather than stop abruptly after more than ~2-3 weeks of therapy.
Counseling should also set expectations: CSU is often self-limited over months to a few years, and the goal is symptom control, not cure.
3. Six months later he develops lip and tongue swelling without hives, and reports he started lisinopril 2 weeks ago for hypertension. How does this change your assessment?
Read the worked answer
This changes the differential substantially. Angioedema without urticaria in a patient on an ACE inhibitor is ACE-inhibitor-associated angioedema until proven otherwise, even if the drug was started recently - onset can be days to years after initiation, and it can recur. The mechanism is bradykinin-mediated, not IgE-mediated, so antihistamines and epinephrine may be less effective and allergy testing is not useful.
The immediate step is to stop lisinopril and document it as a contraindication. Because ACE-inhibitor angioedema can recur for days to weeks after discontinuation, he needs observation and a clear plan for airway warning signs. He should not be switched to another ACE inhibitor; an ARB is generally acceptable (cross-reactivity risk is low), though some clinicians avoid ARBs after severe episodes - this is a judgment call to discuss. He should also be evaluated for hereditary angioedema if episodes continue off the drug, since recurrent angioedema without urticaria warrants complement studies (C4, C1 inhibitor level and function). The prior CSU history does not explain this new pattern, so do not anchor on it.